0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Please Wait... Processing your request... Please Wait.

Not a subscriber yet?

Each month JAMA Oncology keeps you up-to-date with the most important advances in the field. Subscribe/Learn More

Current Highlights

Follow Us

Original Investigation | September 22, 2016 FREE ONLINE FIRST

HCC Surveillance With MRI

This clinical trial examines the hepatocellular carcinoma detection rate using ultrasonography compared with magnetic resonance imaging in patients with cirrhosis who are at high risk for hepatocellular carcinoma.

Original Investigation | September 15, 2016 ONLINE FIRST

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

This meta-analysis examines the prognostic value of minimal residual disease assessment as associated with survival outcomes in patients with newly diagnosed multiple myeloma.
Editorial

Original Investigation | September 9, 2016 ONLINE FIRST

Patient-Centered Communication Intervention in Advanced Cancer

This cluster randomized trial compares the effects of communication training for oncologists combined with communication coaching for patients with advanced cancer and caregivers vs no training or coaching for either on patient-centered communication in the last 30 days of life.

Original Investigation | September 8, 2016 ONLINE FIRST

Prognostic Factors for Local Control in Breast Cancer With Boost vs No Boost

This reanalysis of the EORTC “boost vs no boost” trial examines the long-term impact of prognostic factors on ipsilateral breast tumor recurrence in patients treated with breast-conserving therapy.
Editorial

Original Investigation | September 1, 2016 ONLINE FIRST

Arginine Deprivation in ASS1-Deficient Malignant Pleural Mesothelioma

This phase 2 randomized clinical trial examines the effect of arginine deprivation plus best supportive care vs best supportive care alone in patients with argininosuccinate synthetase 1–deficient malignant pleural mesothelioma.
Invited Commentary

Explore more articles:  Current Issue | Online First

Multimedia >

Author Interview

Author photo

Interview with Conny Vrieling, MD PhD, author of Prognostic Factors For Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial

audio player

RELATED ARTICLE:

Prognostic Factors For Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial A Randomized Clinical Trial

All Author Interviews >

Author Readings
Author photo

audio player

RELATED ARTICLE:


Latest Quiz

All Quizzes >

Skin Lesions, Recurrent Fever, and Acute Myeloid Leukemia

A 69-year-old man with a history of relapsed acute myeloid leukemia monocytic type presented with intermittent fever and fatigue 2 months after allogeneic stem cell transplantation; home medications included acyclovir, fluconazole, and cyclosporine.

What is your diagnosis?

Image of JAMA forum logo

Physician Jobs